Trial · NCT04458922
Adverse events498
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 498
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 0 | 9 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 1 | 9 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Arm 1 Atezolizumab 1200 mg Intravenous on Day 1, Subgroup 3: Dedifferentiated Chondrosarcoma (CS) | 0 | 9 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 2 | 9 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 1 | 9 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Arm 1 Atezolizumab 1200 mg Intravenous on Day 1, Subgroup 3: Dedifferentiated Chondrosarcoma (CS) | 1 | 9 | 1 |
| other | Adrenal insufficiency | Endocrine disorders | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 1 | 9 | 1 |
| other | Adrenal insufficiency | Endocrine disorders | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 0 | 9 | 0 |
| other | Adrenal insufficiency | Endocrine disorders | Arm 1 Atezolizumab 1200 mg Intravenous on Day 1, Subgroup 3: Dedifferentiated Chondrosarcoma (CS) | 0 | 9 | 0 |
| other | Alanine aminotransferase increased | Investigations | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 2 | 9 | 2 |
| other | Alanine aminotransferase increased | Investigations | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 1 | 9 | 1 |
| other | Alanine aminotransferase increased | Investigations | Arm 1 Atezolizumab 1200 mg Intravenous on Day 1, Subgroup 3: Dedifferentiated Chondrosarcoma (CS) | 0 | 9 | 0 |
| other | Alkaline phosphatase increased | Investigations | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 1 | 9 | 1 |
| other | Alkaline phosphatase increased | Investigations | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 0 | 9 | 0 |
| other | Alkaline phosphatase increased | Investigations | Arm 1 Atezolizumab 1200 mg Intravenous on Day 1, Subgroup 3: Dedifferentiated Chondrosarcoma (CS) | 3 | 9 | 3 |
| other | Anemia | Blood and lymphatic system disorders | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 7 | 9 | 17 |
| other | Anemia | Blood and lymphatic system disorders | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 1 | 9 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Arm 1 Atezolizumab 1200 mg Intravenous on Day 1, Subgroup 3: Dedifferentiated Chondrosarcoma (CS) | 4 | 9 | 6 |
| other | Anorexia | Metabolism and nutrition disorders | Arm 1 Atezolizumab 1200 mg Intravenous (IV) on Day 1, Subgroup 1: Clear Cell Sarcoma (CCS) | 7 | 9 | 11 |
| other | Anorexia | Metabolism and nutrition disorders | Arm 1 Atezolizumab 1200 mg IV on Day 1, Subgroup 2: Conventional Chondrosarcoma (CS)(Grade 2 or 3) | 0 | 9 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04458922/events